Erratum: Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation (PLoS ONE (2014) 9:1 (e86619) DOI:10.1371/journal.pone.0086619);Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  El Serafi, Ibrahim ^a   Abedi Valugerdi, Manuchehr ^a   Potácová, Zuzana ^a,b   Afsharian, Parvaneh ^a,c   Mattsson, Jonas ^b   Moshfegh, Ali ^a   Hassan, Moustapha ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD135 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN ANGPTL1; PROTEIN C JUN; PROTEIN GZMB; PROTEIN PRF1; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL ARTICLE; DOWN REGULATION; FOLLOW UP; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC IDENTIFICATION; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOREACTIVITY; PROTEIN EXPRESSION; SCHOOL CHILD; T LYMPHOCYTE RECEPTOR GENE; UPREGULATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CLUSTER ANALYSIS; CYCLOPHOSPHAMIDE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSCRIPTOME; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84898613733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093239     Document Type: Erratum

References (63)

1. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, et al. (2008) Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA : the journal of the American Medical Association 299: 925-936.
2. Reynolds M, McCann SR (1989) A comparison between regimens containing chemotherapy alone (busulfan and cyclophosphamide) and chemotherapy (V. RAPID) plus total body irradiation on marrow engraftment following allogeneic bone marrow transplantation. Eur J Haematol 43: 314-320. (Pubitemid 20022005)
3. Daleboudt GM, Reinders ME, den Hartigh J, Huizinga TW, Rabelink AJ, et al. (2013) Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 22: 171-179.
4. Binotto G, Trentin L, Semenzato G (2003) Ifosfamide and cyclophosphamide: effects on immunosurveillance. Oncology 65: 17-20. (Pubitemid 37346725)
5. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacology & therapeutics 37: 301-355.
6. Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, et al. (2004) Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metabolism and Disposition 32: 1341-1344.
7. Chang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637. (Pubitemid 23360263)
8. Ren S, Yang JS, Kalhorn TF, Slattery JT (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57: 4229-4235. (Pubitemid 27413430)
9. Xie H, Griskevicius L, Stahle L, Hassan Z, Yasar U, et al. (2006) Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 27: 54-61. (Pubitemid 41728255)
10. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, et al. (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15: 861-873. (Pubitemid 41666768)
11. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, et al. (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics 15: 1-5. (Pubitemid 43205520)
12. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, et al. (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319: 1322-1326. (Pubitemid 38759555)
13. Eroglu C, Pala C, Kaynar L, Yaray K, Aksozen MT, et al. (2013) Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma.
14. de Jonge HJ, Huls G, de Bont ES (2011) Gene expression profiling in acute myeloid leukaemia. The Netherlands journal of medicine 69: 167-176.
15. Mills K (2008) Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Front Biosci 13: 4605-4616.
16. Khokher S, Qureshi MU, Mahmood S, Nagi AH (2013) Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev 14: 3223-3228.
17. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, et al. (2008) Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112: 3425-3433.
18. Ringden O, Horowitz MM, Sondel P, Gale RP, Biggs JC, et al. (1993) Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 81: 1094-1101. (Pubitemid 23054851)
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825-828.
20. Remberger M, Ringden O, Hagglund H, Svahn BM, Ljungman P, et al. (2013) A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant 27: E368-374.
21. Soudais C, de Villartay JP, Le Deist F, Fischer A, Lisowska-Grospierre B (1993) Independent mutations of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency. Nat Genet 3: 77-81. (Pubitemid 23063293)
22. Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7: 622-632. (Pubitemid 47123550)
23. Kaufman A, Herold KC (2009) Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev 25: 302-306.
24. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, et al. (1999) A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. European journal of immunology 29: 3596-3602. (Pubitemid 29527807)
25. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (New York, N Y) 270: 985-988.
26. Ting JP, Trowsdale J (2002) Genetic control of MHC class II expression. Cell 109 Suppl: S21-33. (Pubitemid 34457849)
27. Luznik L, Fuchs EJ (2010) High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 47: 65-77.
28. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, et al. (2013) T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 31: 1310-1316.
29. Luznik L, O'Donnell PV, Fuchs EJ (2012) Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 39: 683-693.
30. Rosado CJ, Buckle AM, Law RH, Butcher RE, Kan WT, et al. (2007) A common fold mediates vertebrate defense and bacterial attack. Science (New York, N Y) 317: 1548-1551. (Pubitemid 47417433)
31. Trapani JA (1995) Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. Australian and New Zealand journal of medicine 25: 793-799.
32. Lopez JA, Susanto O, Jenkins MR, Lukoyanova N, Sutton VR, et al. (2013) Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood 121: 2659-2668.
33. Martino A, Holmes JHt, Lord JD, Moon JJ, Nelson BH (2001) Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. Journal of Immunology 166: 1723-1729.
34. Cao J, Jin Y, Li W, Zhang B, He Y, et al. (2013) DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol 14: 39.
35. Matias BF, de Oliveira TM, Rodrigues CM, Abdalla DR, Montes L, et al. (2013) Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer. Clin Med Insights Oncol 7: 165-172.
36. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Research 72: 3439-3444.
37. Wennerberg K, Rossman KL, Der CJ (2005) The Ras superfamily at a glance. J Cell Sci 118: 843-846. (Pubitemid 40484876)
38. Goodsell DS (1999) The molecular perspective: the ras oncogene. Stem Cells 17: 235-236.
39. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Research 49: 4682-4689.
40. El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, et al. (2011) Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood 117: 2146-2156.
41. McCormack MP, Curtis DJ (2010) The thymus under siege: Lmo2 induces precancerous stem cells in a mouse model of T-ALL. Cell Cycle 9: 2267-2268.
42. McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, et al. (2010) The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science (New York, N Y) 327: 879-883.
43. Kearsey SE, Labib K (1998) MCM proteins: evolution, properties, and role in DNA replication. Biochimica et biophysica acta 1398: 113-136. (Pubitemid 28305206)
44. Mantovani A, Bonecchi R, Martinez FO, Galliera E, Perrier P, et al. (2003) Tuning of innate immunity and polarized responses by decoy receptors. Int Arch Allergy Immunol 132: 109-115. (Pubitemid 37409841)
45. Moschella F, Valentini M, Arico E, Macchia I, Sestili P, et al. (2011) Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res 71: 3528-3539.
46. Dale M, Nicklin MJ (1999) Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 57: 177-179. (Pubitemid 29187954)
47. Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, et al. (2013) Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin Cancer Res 19: 4249-4261.
48. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, et al. (1993) Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82: 1110-1119. (Pubitemid 23253983)
49. Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ, et al. (2013) Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. The Journal of clinical investigation 123: 1082-1095.
50. Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI (1996) Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Research 56: 305-315. (Pubitemid 26026359)
51. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, et al. (1999) cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070. (Pubitemid 29535018)
52. Zhang Y, Pu X, Shi M, Chen L, Song Y, et al. (2007) Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 7: 145.
53. Zhang HS, Yan B, Li XB, Fan L, Zhang YF, et al. (2012) PAX2 protein induces expression of cyclin D1 through activating AP-1 protein and promotes proliferation of colon cancer cells. Journal of Biological Chemistry 287: 44164-44172.
54. Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ (2006) c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37: 668-674. (Pubitemid 43956532)
55. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, et al. (2010) c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 285: 8218-8226.
56. Wisdom R, Johnson RS, Moore C (1999) c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. The EMBO journal 18: 188-197. (Pubitemid 29005035)
57. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, et al. (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes & development 13: 607-619. (Pubitemid 29131884)
58. Kollmann K, Heller G, Ott RG, Scheicher R, Zebedin-Brandl E, et al. (2011) c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5′ region of Cdk6. Blood 117: 4065-4075.
59. Ritke MK, Bergoltz VV, Allan WP, Yalowich JC (1994) Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol 48: 525-533. (Pubitemid 24257015)
60. Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D (1992) cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res 52: 878-882.
61. Zhou J, Gupta K, Yao J, Ye K, Panda D, et al. (2002) Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 277: 39777-39785. (Pubitemid 35190961)
62. Gurzov EN, Bakiri L, Alfaro JM, Wagner EF, Izquierdo M (2008) Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene 27: 641-652. (Pubitemid 351158900)
63. Xia Y, Yang W, Bu W, Ji H, Zhao X, et al. (2013) Differential Regulation of c-Jun Protein Plays an Instrumental Role in Chemoresistance of Cancer Cells. Journal of Biological Chemistry 288: 19321-19329.